Thanks for the DD and sharing the results. Great post which needs to be stickied.
Highlights the important points in the last 10Q:
...11/8/2018 10Q shows IPIX is in discussions for all of its pharmaceuticals with multiple companies including multiple global and specialty companies. The company may be party to discussions and term sheets including for both global and/or territorial licensing {my summary}:
The serial reports in your post confirm the progression in IPIX's confidence with potential partnership and licensing agreements.
From 5/2018
" ...we released results from our completed Phase 2 Brilacidin study on Oral Mucositis. The results have attracted inquiries, additional confidential disclosure agreements, and discussions with pharmaceutical companies"
From the 1OK in 9/2018:
"The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence..."
Now the 11/8/2018 10Q shows IPIX is in discussions for all of its pharmaceuticals with multiple companies including multiple global and specialty companies. The company may be party to discussions and term sheets including for both global and/or territorial licensing:
{The first sentence is new information}
"The Company is actively engaged in business development and licensing initiatives with multiple specialty and global pharmaceutical companies across its entire pipeline of drugs. From time to time, the Company may be party to various indications of interest and term sheets and participate in preliminary discussions and negotiations regarding potential licensing or partnership arrangements. It remains the Company’s primary objective to complete licensing deals, territorial and/or global, to provide access to non-dilutive capital to advance clinical assets forward in the most expeditious and cost-effective manner. The Company can make no assurance that partnerships will occur, but is committed toward executing on these potential alliance and partnership opportunities.
GLTA Farrell
